BBIO - What's Going On With BridgeBio Pharma Stock Today? | Benzinga
BridgeBio Pharma Inc (NASDAQ: BBIO) announced the presentation of detailed results from its Phase 3 ATTRibute-CM study of acoramidis for ATTR-CM at the European Society of Cardiology Congress 2023.
Transthyretin amyloidosis (ATTR-CM) is a buildup of faulty proteins (fibrils) on the heart or nerves, making the heart weak to pump blood.
In July, BridgeBio announced topline results from ATTRibute-CM.
A highly statistically significant result, demonstrated by a Win Ratio of 1.8 (p<0.0001), was observed on the primary endpoint ...